Source author record

Kaspar Rufibach

Kaspar Rufibach appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

4works
3topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

4 published item(s)

preprint2022arXiv

Applying the Estimand and Target Trial frameworks to external control analyses using observational data: a case study in the solid tumor setting

In causal inference, the correct formulation of the scientific question of interest is a crucial step. Here we apply the estimand framework to a comparison of the outcomes of patient-level clinical trials and observational data to help structure the clinical question. In addition, we complement the estimand framework with the target trial framework to address specific issues in defining the estimand attributes using observational data and discuss synergies and differences of the two frameworks. Whereas the estimand framework proves useful to address the challenge that in clinical trials and routine clinical practice patients may switch to subsequent systemic therapies after the initially assigned systematic treatment, the target trial framework supports addressing challenges around baseline confounding and the index date. We apply the combined framework to compare long-term outcomes of a pooled set of three previously reported randomized phase 3 trials studying patients with metastatic non-small cell lung cancer receiving front-line chemotherapy (randomized clinical trial cohort) and similar patients treated with front-line chemotherapy as part of routine clinical care (observational comparative cohort). We illustrate the process to define the estimand attributes and select the estimator to estimate the estimand of interest while accounting for key baseline confounders, index date, and receipt of subsequent therapies. The proposed combined framework provides more clarity on the causal contrast of interest and the estimator to adopt and thus facilitates design and interpretation of the analyses.

preprint2014arXiv

Maximum-Likelihood Estimation of a Log-Concave Density based on Censored Data

We consider nonparametric maximum-likelihood estimation of a log-concave density in case of interval-censored, right-censored and binned data. We allow for the possibility of a subprobability density with an additional mass at $+\infty$, which is estimated simultaneously. The existence of the estimator is proved under mild conditions and various theoretical aspects are given, such as certain shape and consistency properties. An EM algorithm is proposed for the approximate computation of the estimator and its performance is illustrated in two examples.

preprint2014arXiv

SurvRegCensCov: Weibull Regression for a Right-Censored Endpoint with a Censored Covariate

Biomarker data is often subject to limits of quantification and/or limits of detection. Statistically, this corresponds to left- or interval-censoring. To be able to associate a censored time-to-event endpoint to a biomarker covariate, the R package SurvRegCensCov provides software for Weibull regression for a right-censored endpoint, one interval-censored, and an arbitrary number of non-censored covariates. Furthermore, the package provides functions to estimate canonical parameters from censored samples based on several distributional assumptions, and a function to switch between different parametrizations used in R for Weibull regression. We illustrate the new software by applying it to assess Prentice's criteria for surrogacy in data simulated from a randomized clinical registration trial.